13 reports

  • ABBREVIATIONS (1/2)

ONLY ONE CETUXIMAB BIOSIMILAR IS UNDER DEVELOPMENT IN THE ##MM, RELIANCE LIFE SCIENCES' R-TPR-##, WHICH IS INVESTIGATED IN AN INDIAN-BASED PHASE III TRIAL IN HEAD AND NECK CANCER.

  • Cancer
  • South Korea
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • 9.2 Growing Incidence of Cancer Patients in South Korea
  • South Korea- Number of Patient Diagnosed With Cancer (Thousand), 2009 - 2016

Korea Proton Therapy Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast is a research study published by Renub Research. According to this research South Korea Proton Therapy Market is expected to almost triple by 2021 from its current market size in 2016. Untapped Proton Therapy Market for South Korea was...

  • Cancer
  • South Korea
  • Demand
  • Market Size
  • Varian Medical Systems, Inc.
  • 7.2 Growing Incidence of Cancer Patients
  • SOUTH KOREA - NUMBER OF PATIENT DIAGNOSED WITH CANCER (NUMBER), 2007 - 2016

South Korea proton therapy market is anticipated to almost three-fold during the period 2016 - 2022. The number of patients treated with Proton Therapy in South Korea is very low whereas; the potential candidates for proton therapy are huge. Unfortunately, the access to proton therapy is limited for a vast population, owing to...

  • Cancer
  • Diagnostic Imaging
  • South Korea
  • Forecast
  • Market Size

South Korea Cancer Demographics ##. ## Incidence by Site ##.

  • Cancer
  • Pathology
  • South Korea
  • Forecast
  • Mar 07, 2016: Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor

Summary Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs.The company’s prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counter products such...

  • Cancer
  • Pharmaceutical
  • Therapy
  • South Korea
  • Hanmi Science Co., Ltd.
  • REGENERON PHARMA AND SILLAJEN BIOTHERAPEUTICS ENTER INTO AGREEMENT
  • SILLAJEN PLANS TO RAISE FUNDS IN IPO

It is designed to enroll ## patients who have not received prior systemic treatment for their cancer, and they will be randomized to one of two treatment groups: one which will receive Pexa-Vec followed by sorafenib and one which will receive sorafenib alone.

  • Cancer
  • Healthcare
  • South Korea
  • M&A
  • BioTherapeutics Inc.
  • HEAD OFFICE
  • Company Overview

Green Cross is one of the Asia' s largest plasma protein product manufacturers.

  • Cancer
  • Pharmaceutical
  • South Korea
  • World
  • Company Financials
  • EQUITY OFFERING

The company' s deal volume increased from one pharmaceuticals & healthcare deal in 2016 to three pharmaceuticals & healthcare deals in 2017.

  • Cancer
  • Healthcare
  • Monoclonal Antibody
  • South Korea
  • Celltrion, Inc.
  • DEBT OFFERING
  • GREEN CROSS CELL RAISES USD55.3 MILLION IN PRIVATE PLACEMENT OF CONVERTIBLE BONDS

The company offers Immuncell-LC, an anti-cancer immune therapeutic that is derived from lymphocytes of cancer patient.

  • Cancer
  • South Korea
  • Company
  • Deals & Alliance
  • Green Cross
  • ASSET TRANSACTIONS

GlobalData Region Asia-Pacific Europe North America South and Central America Middle East and Africa No. of Deals ## ## ## ## NA Deal Value (US$ million) NA NA NA NA NA Samyang Biopharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to Y

  • Biopharmaceutical
  • Cancer
  • South Korea
  • Deals & Alliance
  • Samyang Biopharmaceuticals Corporation
  • PARTNER 1: CELLTRION INC
  • PARTNER 3: CELLTRION INC

ORChem Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline’s ORChem Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments,...

  • Cancer
  • Gastroenterology
  • Pharmaceutical
  • South Korea
  • Celltrion, Inc.
  • Dec 21, 2017: Identified the mechanism of apoptosis gene that is involved in the resistance to cancer treatment
  • Sep 08, 2017: Identification of new protein function that activates the harmful protein dissolution in the cell

It is urgent to develop treatment for infection with super bacteria, which is resistant to antibiotics and cancer metastasis which is the movement of cancer cell to other parts of human body is regarded as major cause of death from cancer.

  • Biotechnology
  • Cancer
  • Pharmaceutical
  • South Korea
  • Deals & Alliance

Although Aptose has two compelling cancer drugs, current resources can support the full development activities of only one at this time.

  • Cancer
  • Healthcare
  • Pharmaceutical
  • South Korea
  • CrystalGenomics, Inc.